Fariba Jousheghany
Researcher
University of Arkansas for Medical Sciences
faculty
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Fariba Jousheghany's research focuses on investigating immune responses in the context of cancer treatment, particularly in breast cancer patients. She has examined the effects of combining cancer vaccines, such as the P10s-PADRE vaccine, with neoadjuvant chemotherapy. Her work includes characterizing the humoral and cellular immune responses induced by these combined treatments, as well as identifying peripheral immune correlates that predict tumor response.
Jousheghany has also explored specific molecular targets in cancer research, including antibodies to chondroitin sulfate proteoglycan 4 (CSPG4) and the role of tumor-associated glycans and scavenger receptor class A in tumor exosome-macrophage interactions. Her publications detail the induction of cancer-specific T-cell responses and the influence of immunization timing on the immune signature of vaccine regimens. She has a h-index of 14 with 41 total publications and 681 total citations. Key collaborators include Behjatolah Monzavi-Karbassi, Bernice Nounamo, Steven R. Post, and Eric R. Siegel, all from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 14
- Publications: 41
- Citations: 681
Selected Publications
- Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment (2024) DOI
- Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine (2024) DOI
- Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A (2024) DOI
- Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine (2023) DOI
- VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen (2023) DOI
- Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients (2022) DOI
- P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses (2021) DOI
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics